跳轉至內容
Merck
全部照片(1)

Key Documents

N-059

Supelco

降丙吗啡标准液 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C25H35NO4
CAS號碼:
分子量::
413.55
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

certified reference material

品質等級

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商/商標名

Cerilliant®

濃度

1.0 mg/mL in methanol

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

forensics and toxicology

格式

single component solution

運輸包裝

wet ice

儲存溫度

−20°C

SMILES 字串

CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4)c56

InChI

1S/C25H35NO4/c1-21(2,3)22(4,28)16-13-23-8-9-25(16,29-5)20-24(23)10-11-26-17(23)12-14-6-7-15(27)19(30-20)18(14)24/h6-7,16-17,20,26-28H,8-13H2,1-5H3/t16-,17-,20-,22+,23-,24+,25-/m1/s1

InChI 密鑰

YOYLLRBMGQRFTN-IOMBULRVSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

A new Certified Spiking Solution® suitable for use in clinical toxicology, forensic testing, or pain prescription monitoring.

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

相關產品

產品號碼
描述
訂價

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes

儲存類別代碼

3 - Flammable liquids

水污染物質分類(WGK)

WGK 1

閃點(°F)

49.5 °F - closed cup

閃點(°C)

9.7 °C - closed cup


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Marta Concheiro et al.
Therapeutic drug monitoring, 33(5), 619-626 (2011-08-24)
Buprenorphine is currently under investigation as a pharmacotherapy to treat pregnant women for opioid dependence. This research evaluates buprenorphine (BUP), norbuprenophine (NBUP), buprenorphine-glucuronide (BUP-Gluc), and norbuprenorphine-glucuronide (NBUP-Gluc) pharmacokinetics after high-dose (14-20 mg) BUP sublingual tablet administration in three opioid-dependent pregnant
Hong K Kim et al.
Pediatrics, 130(6), e1700-e1703 (2012-11-07)
Buprenorphine is a partial μ-opioid receptor agonist that is approved for the treatment of opioid dependency. It is generally believed to be safer than methadone because of its ceiling effect on respiratory depression. As more adults in US households use
Giuseppe Lippi et al.
Journal of clinical laboratory analysis, 25(4), 244-245 (2011-07-26)
Buprenorphine is a centrally acting analgesic drug that is administered for the management of opioid dependence and as an analgesic drug for the treatment of chronic pain. The growing use of this substance has determined an increased need for laboratory
Tor Seldén et al.
Forensic science international, 220(1-3), 284-290 (2012-05-09)
Buprenorphine is considered to have little respiratory side effects at therapeutic doses and the partial agonistic properties should produce a "ceiling effect" for respiratory depression at higher doses. Still, there are several reports on buprenorphine related deaths. Most deaths involve
Kenneth F Ilett et al.
Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine, 7, 269-274 (2011-10-21)
The aim of the present study was to estimate the dose of buprenorphine and its primary metabolite norbuprenorphine that a breastfed infant would receive during maternal maintenance treatment with buprenorphine. Seven pregnant opioid-dependent women taking buprenorphine (median, 7 mg/day; range, 2.4-24 mg)

條款

To optimize hydrolysis using β-glucuronidase, factors such as incubation time, temperature, hydrolysis pH, enzyme source, and enzyme concentration must be evaluated for each glucuronide metabolite to be analyzed.

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務